TrialInvestigational new drugs2013

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Harry P Erba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.